46 completed, 10 terminated, 8 active not recruiting, 4 recruiting. 74 Phase 2, 7 Phase 1, 3 Phase 3.
Follow Urethral Diseases: new trials by email Literature Review of Urethral Diseases trials Research Report on Urethral Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Omadacycline for Treatment Refractory Mycoplasma Genitalium Urethritis Omadacycline Oral Tablet - Mycoplasma Genitalium Infection, Urethritis | Phase 2 | Not yet recruiting | Montefiore Medical Center | 10 | 2026-10-01 | 2026-10-02 |
| LishitonglinUS-01 Trial Lishitonglin Formula granules, Oral placebo medication formulated as granules - Urethra Stricture | Phase 2 | Active not recruiting | Peking University First Hospital | 120 | 2026-01-09 | 2026-08-17 |
| Clinical Trial of AM80 in Combination With Gemcitabine, Cisplatin, and Nivolumab in Patients With Urothelial Carcinoma Add-on effect of adding tamivarotene (AM80) to gemcitabine, cisplatin, and nivolumab combination therapy - Urothelial Carcinoma Bladder, Urothelial Carcinoma of the Renal Pelvis and Ureter | Phase 2 | Recruiting | Nagoya University | 43 | 2025-05-01 | 2025-08-14 |
| Agnostic Therapy in Rare Solid Tumors Nivolumab - Urachal Cancer, Parathyroid Carcinoma | Phase 2 | Active not recruiting | Instituto do Cancer do Estado de São Paulo | 28 | 2024-07-16 | 2026-10-13 |
| Autologous Muscle Stem Cell Therapy for Treatment of Congenital Urinary Incontinence in Epispadias Patients Primary human muscle stem cells (Satori-01), Placebo - Urinary Incontinence, Epispadias, Male | Phase 1 / Phase 2 | Not yet recruiting | Simone Spuler, MD | 21 | 2024-06-01 | 2023-08-03 |
| Safety and Potential Effect of Innovative Treatment by Adjuvant Injection of Stromal Vascular Fraction From Autologous Adipose Tissue of URethral Stenosis With Endoscopic Urethrotomy lipoaspiration, urethrotomy, autologous ADSVF administration - Urethral Stenosis | Phase 2 | Recruiting | Assistance Publique Hopitaux De Marseille | 20 | 2024-03-13 | 2026-02-04 |
| 64Cu-GRIP B in Patients With Advanced Malignancies Copper-64 labeled Granzyme B (64Cu-GRIP B), Positron Emission Tomography (PET) - Prostate Cancer, Renal Cancer | Phase 1 / Phase 2 | Recruiting | Rahul Aggarwal | 91 | 2023-05-25 | 2026-03-17 |
| Intralesional Injection of Mitomycin C Following Visual Internal Urethrotomy for Recurrent Urethral Stricture Mitomycin c - Urethral Stricture | Phase 2 / Phase 3 | Completed | Ain Shams University | 50 | 2022-01-01 | 2024-01-30 |
| Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma Ipilimumab, Nivolumab, Tocilizumab - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 35 | 2021-09-23 | 2026-09-16 |
| ARID1A and/or KDM6A Mutation and CXCL13 Expression Diagnostic Laboratory Biomarker Analysis, Nivolumab, Relatlimab - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 6 | 2021-09-21 | 2026-10-06 |
| Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma Pembrolizumab, Propranolol Hydrochloride, Nivolumab - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma | Phase 2 | Active not recruiting | Emory University | 6 | 2021-05-20 | 2026-02-19 |
| Clostridium Histolyticum Collagenase Injection for Urethral Disease Clostridium Histolyticum Collagenase, Saline - Urethral Stricture | Phase 2 | Completed | University of South Florida | 5 | 2020-05-22 | 2023-11-03 |
| Post-Operative Imaging After Urethroplasty With Peri-catheter Retrograde Urethrography Or Trial of Voiding With Voiding Cysto-urethrography Post-urethroplasty urethrography - Urethral Stricture | Phase 2 | Completed | University Hospital, Ghent | 80 | 2020-01-21 | 2023-01-04 |
| Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma Atezolizumab, Biopsy, Biospecimen Collection - Advanced Bladder Urothelial Carcinoma, Advanced Ureter Urothelial Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 47 | 2019-06-05 | 2024-07-26 |
| Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors Biospecimen Collection, Bone Scan, Cabozantinib S-malate - Bladder Adenocarcinoma, Bladder Clear Cell Adenocarcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 314 | 2019-05-13 | 2026-10-28 |
| Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer Avelumab, Cisplatin, Fluorouracil - Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Stage II Bladder Cancer AJCC v8 | Phase 2 | Completed | Mayo Clinic | 2 | 2018-09-19 | 2023-01-06 |
| Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer Atezolizumab, Biopsy Procedure, Biospecimen Collection - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 72 | 2018-07-20 | 2026-07-31 |
| Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Rucaparib - Bladder Cancer, Urothelial Carcinoma | Phase 2 | Terminated | pharmaand GmbH | 97 | 2018-06-01 | 2023-06-09 |
| Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma Atezolizumab, Guadecitabine - Urothelial Carcinoma | Phase 2 | Active not recruiting | Fox Chase Cancer Center | 21 | 2017-11-27 | 2021-11-04 |
| A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer enfortumab vedotin (EV), pembrolizumab, cisplatin - Carcinoma, Transitional Cell, Urinary Bladder Neoplasms | Phase 1 / Phase 2 | Terminated | Astellas Pharma Global Development, Inc. | 348 | 2017-10-11 | 2026-03-24 |
Showing 20 of 74. Sign in to see all of them.
Urethral Neoplasms (58) · Urinary Bladder Neoplasms (53) · Ureteral Neoplasms (25) · Carcinoma, Transitional Cell (13) · Urethral Stricture (8) · Urethritis (4) · Urinary Bladder Neck Obstruction (3) · Carcinoma, Renal Cell (2) · Kidney Neoplasms (2) · Lower Urinary Tract Symptoms (2) · Neoplasms (2) · Penile Neoplasms (2) · Prostatic Neoplasms (2) · Urachal adenocarcinoma (2) · Urachal cancer (2)
Female Urogenital Diseases (74) · Female Urogenital Diseases and Pregnancy Complications (74) · Male Urogenital Diseases (74) · Urogenital Diseases (74) · Urologic Diseases (74) · Neoplasms by Site (58) · Neoplasms (57) · Urogenital Neoplasms (57) · Urinary Bladder Diseases (56) · Urologic Neoplasms (56) · Ureteral Diseases (25) · Neoplasms by Histologic Type (16) · Carcinoma (15) · Neoplasms, Glandular and Epithelial (15)
Gemcitabine (19) · Cisplatin (12) · Carboplatin (6) · Paclitaxel (6) · Nivolumab (5) · Fluorouracil (4) · Doxorubicin (3) · Magnetic Resonance Spectroscopy (3) · Radiotherapy (3) · Specimen Handling (3) · Sunitinib (3) · atezolizumab (3) · Biopsy (2) · CTLA-4 Antigen (2) · Docetaxel (2)
National Cancer Institute (NCI) (12) · M.D. Anderson Cancer Center (6) · SWOG Cancer Research Network (6) · Eastern Cooperative Oncology Group (4) · Astellas Pharma Inc (3) · Cardiff University (3) · European Organisation for Research and Treatment of Cancer - EORTC (3) · Ain Shams University (2) · Memorial Sloan Kettering Cancer Center (2) · Achieve Life Sciences (1) · Altor BioScience (1) · Assistance Publique Hopitaux De Marseille (1) · Astellas Pharma Global Development, Inc. (1) · AstraZeneca (1) · Centers for Disease Control and Prevention (1)
United States (48) · Spain (7) · United Kingdom (7) · Canada (6) · France (6) · Germany (6) · Italy (6) · Netherlands (5) · Belgium (4) · Israel (3) · Puerto Rico (3) · South Africa (3) · Brazil (2) · China (2) · Denmark (2)
Daniel P. Petrylak, MD (2) · Dean F. Bajorin, MD (2) · Robert Dreicer (2) · Robert Dreicer, MD, FACP (2) · Andrea B Apolo (1) · Andrea B Apolo, M.D. (1) · Andrea Necchi, MD (1) · Andrey A Pulin, MD, PhD (1) · Andrey Z Vinarov, MD, PhD, Prof (1) · Anishka A D'Souza (1) · Anne K Ebert, Prof. Dr. (1) · Anne Olaug Olsen, MD, PhD (1) · Arif Hussain (1)
PMID 12448661, PMID 12767086, PMID 15541123, PMID 15911238, PMID 16080084, PMID 17437780, PMID 17617144, PMID 18459175, PMID 18501081, PMID 19269798, PMID 19371909, PMID 19786668, PMID 21288838, PMID 21315996, PMID 22162575, PMID 22819172, PMID 22831853, PMID 23329066, PMID 23376148, PMID 24745607, PMID 25427282, PMID 26126692, PMID 26149529, PMID 26491251, PMID 26582660, PMID 26926681, PMID 27165786, PMID 31356140, PMID 31390274, PMID 31648851, PMID 32645282, PMID 33991512, PMID 34030643, PMID 35031545, PMID 35168844, PMID 35537412, PMID 36041086, PMID 37328287, PMID 37369081, PMID 38215355, PMID 38849479, PMID 9679876
U10CA032102 (6), U10CA031946 (3), U10CA021115 (2), 2017 (1), N01CM00038 (1), N01CM62201 (1), N01CM62205 (1), N01CM62209 (1), P30CA014599 (1), P30CA015704 (1), P30CA016672 (1), P30CA093373 (1), P30CA138292 (1), P50CA091846 (1), R01CA229354 (1)